Assenagon Asset Management
ACRS icon

Assenagon Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Assenagon Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818K Sell
154,554
-22,729
-13% -$101K ﹤0.01% 1001
2026
Q1 		$665K Buy
177,283
+22,729
+15% +$76.7K ﹤0.01% 964
2025
Q4 		$465K Hold
154,554
– – ﹤0.01% 1052
2025
Q3 		$294K Sell
154,554
-30,031
-16% -$52.4K ﹤0.01% 1106
2025
Q2 		$262K Sell
184,585
-496,968
-73% -$672K ﹤0.01% 1098
2025
Q1 		$1.04M Buy
681,553
+284,191
+72% +$606K ﹤0.01% 888
2024
Q4 		$985K Buy
397,362
+211,585
+114% +$526K ﹤0.01% 1105
2024
Q3 		$214K Buy
+185,777
New +$228K ﹤0.01% 1327
2023
Q4 		– Sell
-687,135
Closed -$4.71M – 1394
2023
Q3 		$4.71M Buy
687,135
+50,306
+8% +$430K 0.01% 598
2023
Q2 		$6.6M Buy
636,829
+211,001
+50% +$1.91M 0.02% 435
2023
Q1 		$3.44M Buy
425,828
+230,905
+118% +$2.93M 0.01% 677
2022
Q4 		$3.07M Hold
194,923
– – 0.01% 672
2022
Q3 		$3.07M Sell
194,923
-98,122
-33% -$1.55M 0.01% 594
2022
Q2 		$4.09M Sell
293,045
-214,390
-42% -$3M 0.02% 606
2022
Q1 		$8.75M Buy
+507,435
New +$6.92M 0.02% 403
2021
Q4 		– Sell
-473,365
Closed -$8.52M – 1412
2021
Q3 		$8.52M Sell
473,365
-103,507
-18% -$1.66M 0.03% 313
2021
Q2 		$10.1M Buy
576,872
+556,283
+2,702% +$12.6M 0.03% 336
2021
Q1 		$519K Buy
+20,589
New +$403K ﹤0.01% 1025
2019
Q3 		– Sell
-82,905
Closed -$182K – 813
2019
Q2 		$182K Buy
+82,905
New +$452K ﹤0.01% 955
2019
Q1 		– Sell
-121,011
Closed -$894K – 920
2018
Q4 		$894K Buy
+121,011
New +$1.25M 0.01% 682

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Assenagon Asset Management's ACRS Position: Q2 2026 in Review

Assenagon Asset Management reduced its Aclaris Therapeutics (ACRS) stake by 13% in Q2 2026, selling an estimated $101K and leaving 154,554 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Assenagon Asset Management first reported a position in ACRS in Q4 2018 and has held it in 20 quarters since. The position peaked at $10.1M in Q2 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Assenagon Asset Management held 154,554 shares of Aclaris Therapeutics worth $818K as of Q2 2026.
  • Assenagon Asset Management sold 22,729 Aclaris Therapeutics shares in Q2 2026, an estimated $101K.
  • Aclaris Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1001 holding.
  • Assenagon Asset Management first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 20 quarters since.
  • Assenagon Asset Management's Aclaris Therapeutics position peaked at $10.1M in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.